Pharmaceutical industry staffing costs 2026: salaries, turnover, and outsourcing data by role

---

Pharmaceutical industry staffing costs 2026: what the numbers actually show

Pharma in 2026 is stuck between two realities that do not fit together comfortably. Specialized talent still commands some of the highest salaries in any sector. An experienced regulatory affairs director or clinical operations lead earns well into six figures, and the competition for those people has not eased. But a $300 billion patent cliff between 2025 and 2030 is forcing companies to cut headcount, restructure, and outsource work they used to own (Fierce Pharma, 2026).

The labor market has shifted fast. Large pharma companies eliminated more than 22,000 positions in 2025 alone (Fierce Pharma, 2026). Voluntary turnover is climbing. Compensation is moving away from equity toward base salary. And CROs keep absorbing work that used to sit inside pharma org charts.

This article pulls 2025 and 2026 data from the Bureau of Labor Statistics, Pharmaceutical Technology, PharmaDiversity, Mercer, Fierce Pharma, and BioSpace. The goal is an accurate baseline for anyone planning a pharma staffing budget this year.

---

1. The patent cliff reshaping every workforce decision

One macro force sits behind nearly every staffing change in pharma right now, and you need to understand it before the salary tables make sense.

• Between 2025 and 2030, approximately $300 billion in branded drug revenues face generic or biosimilar competition as key patents expire. This is the largest patent cliff the industry has faced (Fierce Pharma, 2026).
• Large pharmaceutical companies with at least $20 billion in 2025 revenue collectively reduced their workforces by more than 22,000 employees last year. By July 2025, the industry had already surpassed 13,000 layoffs, a 31 percent year-over-year increase at the halfway mark (BioSpace Layoff Tracker, 2025).
• Novo Nordisk announced plans to cut roughly 9,000 positions, about 11.5 percent of its workforce, as part of a restructuring targeting $1.26 billion in annual savings (Fierce Pharma, 2026).
• Merck laid off approximately 6,000 employees, around 8 percent of its global headcount, in mid-2025 (BioSpace, 2025).
• Bayer reduced its global workforce from approximately 100,000 to 88,000 through a multi-year reorganization under CEO Bill Anderson (BioSpace, 2025).
• Takeda's multi-year transformation program targets about 4,500 roles during fiscal year 2026. The company is centralizing corporate functions and flattening management layers (Fierce Biotech, 2026).
• CSL announced plans to lay off about 15 percent of its workforce and close 22 plasma centers in the United States (BioSpace, 2025).

These are not one-off cost cuts. The revenue base is shrinking on legacy products while R&D pipelines still need sustained investment. That math forces a different approach to labor budgets.

---

2. Salaries by role: 2026 national data

Pharma pay is still among the highest in any industry. What is changing is the mix: base salaries are going up while equity grants and bonuses are shrinking.

Research and development

Regulatory affairs

Sales and commercial

Manufacturing and quality

Administrative and support

Across the board, U.S. pharmaceutical sciences professionals earned an average base salary of $191,800 in 2024, up 4.5 percent from the prior year. Full-time life sciences employees saw average salaries rise about 9 percent from 2023 to 2024 (PharmaDiversity Salary Survey, 2025).

---

3. Compensation structure shifts: less equity, more base

The way pharma companies pay people is changing as fast as the amounts.

• The share of professionals receiving bonuses dropped from 71 percent in 2023 to 69 percent in 2024 (PharmaDiversity, 2025).
• Equity-based compensation fell sharply. Only 30 percent of pharma professionals received equity in 2024, down from 36 percent in 2023. The average equity value dropped from $86,376 to $60,776 (PharmaDiversity, 2025).
• Combined salary satisfaction fell from 54.8 percent ("fully" or "mostly" satisfied) in the 2024 survey to 52.3 percent in the 2025 survey (Pharmaceutical Technology, 2025).
• The percentage of respondents who changed jobs involuntarily within the past two years nearly doubled, from 14.5 percent in 2024 to 27.3 percent in 2025 (Pharmaceutical Technology, 2025).

The practical effect: pharma companies are concentrating compensation into base salaries while pulling back on the equity and bonus structures that used to tie talent to longer tenures. Base payroll is growing even when total compensation stays flat or declines. If you are budgeting for headcount, this matters.

---

4. Turnover and retention: the cost of losing specialized talent

Pharma turnover rates are still below the national average. But they are climbing, and the cost per departure is unusually high because of how specialized most roles are.

• Voluntary turnover in the biopharma sector rose from 13.7 percent in 2024 to 15.9 percent in 2025 (Pharmaceutical Technology, 2025 Bio/Pharma Workforce Survey).
• LinkedIn data shows approximately 61,000 open job vacancies across U.S. pharmaceutical companies, an implied vacancy rate of about 8 percent (PharmExec, 2025).
• Replacing a specialized pharmaceutical employee costs between 100 and 200 percent of their annual salary. For clinical trial leads or regulatory affairs managers, the total cost can exceed $500,000 once you factor in delays, lost productivity, and compliance risks (Retensa, 2025).
• Burnout is a big part of this. The industry hired aggressively during the pandemic boom and then pulled back. The people who stayed are managing larger workloads (PharmaVoice, 2025).
• The Inflation Reduction Act's drug pricing negotiations are adding another layer of uncertainty. Companies facing price reductions on top products are pulling forward headcount adjustments that might otherwise have happened over two or three years (Fierce Pharma, 2026).

Run the math for a mid-size pharma company with 5,000 employees and a 15.9 percent voluntary turnover rate. That is 795 departures per year. At an average replacement cost of $150,000 for specialized roles, the annual bill is roughly $119 million. That number alone justifies real money going to retention. The irony is that many companies are cutting retention budgets alongside the layoffs.

---

5. SG&A and labor as a share of revenue

Pharma companies spend a larger share of revenue on selling, general, and administrative costs than most people expect.

• Johnson & Johnson reported selling, marketing, and administrative expenses at 25.7 percent of total sales in fiscal year 2024 (J&J Annual Report, 2025).
• AstraZeneca had one of the highest SG&A-to-revenue ratios among major pharma companies in 2024, followed by GSK and Roche (Statista, 2025).
• R&D expenses typically add another 15 to 25 percent of revenue on top of SG&A, meaning that for large pharma, labor-driven costs (SG&A plus R&D headcount) can account for 40 to 50 percent of total revenue (Hardman & Co, 2025 Pharma Statistics).
• Cost of goods sold in pharmaceutical manufacturing is relatively low compared to other manufacturing sectors, typically 20 to 35 percent of revenue, which means labor and overhead account for the majority of operating expenses (Hardman & Co, 2025).
• Unit labor costs in U.S. pharmaceutical manufacturing have risen steadily, tracking above the broader manufacturing sector average (Federal Reserve Bank of St. Louis, FRED, 2025).

The pressure from patent expirations is compressing the revenue side while labor costs remain sticky. That compression explains why so many companies are restructuring simultaneously: the operating model that worked with blockbuster margins does not work when generics erode 30 to 50 percent of a product's revenue within 18 months of patent expiry.

---

6. Contract research organizations: the outsourcing accelerator

The CRO market is the clearest indicator of where pharma labor dollars are going. Companies are trading fixed headcount for variable outsourced capacity.

• The global contract research organization market reached $60.7 billion in 2025 and is projected to hit $65.2 billion in 2026 (Coherent Market Insights, 2025).
• North America accounts for 44.5 percent of the global CRO market (MarketsandMarkets, 2025).
• Clinical trial outsourcing keeps growing as pharma companies shrink internal clinical operations teams. Many companies that expanded trial capacity through CROs during COVID vaccine development decided the model worked well enough to keep (Fortune Business Insights, 2025).
• The pharmaceutical services outsourcing market, which includes both CROs and contract manufacturing organizations, is growing at a compound annual rate of approximately 7.1 percent (Market.us, 2025).
• Asia-Pacific is the fastest growing CRO region, mostly because labor costs for clinical monitoring, data management, and regulatory writing are lower there (Mordor Intelligence, 2025).

What this means for staffing budgets: many roles that used to be internal pharma headcount now show up as vendor line items in procurement. A clinical research associate on a CRO's payroll costs the pharma sponsor 40 to 60 percent less than the same role in-house once you account for benefits, training, bench time between studies, and overhead.

---

7. Contract and temporary staffing patterns

Beyond CROs, pharma companies are using temporary and contract staffing more broadly across commercial and administrative functions.

• Contract staffing in pharmaceutical sales surged during the launch of GLP-1 receptor agonists and oncology products in 2024 and 2025. Companies preferred contract sales organizations over building permanent field forces for products where the long-term market position was uncertain (Staffing Industry Analysts, 2025).
• Temporary regulatory affairs professionals are in high demand for submission preparation, with day rates for experienced regulatory consultants running $800 to $1,500 depending on therapeutic area and submission type (Panda International, 2025).
• Manufacturing contract labor use has increased at pharma plants expanding capacity for biologics and cell and gene therapy products, where the learning curve for permanent hires is steep and production schedules are unpredictable (Pharmaceutical Technology, 2025).
• The blended cost of a contract pharmaceutical scientist, including agency markup, typically runs 1.3 to 1.6 times the base salary equivalent, compared to a fully loaded internal employee cost multiplier of 1.25 to 1.4 times base salary. The trade-off is flexibility versus the premium (Mercer, 2025 Total Remuneration Survey).

The contract staffing model works well for project-based work like clinical trial ramp-ups, regulatory submissions, and product launches. It works less well for roles requiring deep institutional knowledge, like pharmacovigilance case processing or long-cycle formulation development, where continuity directly affects quality and compliance outcomes.

---

8. The loaded cost of a pharmaceutical employee

Base salary is one number. The fully loaded cost, including benefits, payroll taxes, and overhead, is the number that matters for budgeting.

For a research scientist with a $97,100 base salary, the fully loaded annual cost ranges from $145,650 to $184,490. For an R&D director at $159,900, loaded costs reach $239,850 to $303,810. These multipliers are higher than the manufacturing or retail sectors because pharma employees typically receive better health benefits, higher 401(k) matches, and work in specialized facilities.

The full cost of hiring an employee matters here because these loaded numbers are what you compare against outsourced alternatives.

---

9. Where administrative costs can be reduced

Not every pharma role requires on-site specialized talent. A number of administrative and support functions work well in outsourced or virtual models, and companies are already moving them.

Functions that pharma companies are shifting to lower cost staffing models:

• Regulatory document formatting, submission tracking, and correspondence management
• Pharmacovigilance case intake and initial triage (non-medical assessment steps)
• Clinical trial site payment processing and invoice reconciliation
• Medical information call center operations (non-clinical inquiries)
• Sample management and inventory tracking for sales teams
• Travel and expense processing for field-based employees
• Vendor management and purchase order coordination
• Meeting and congress logistics coordination
• CRM data entry and territory alignment updates
• Literature search and reference management for medical affairs

Functions that typically stay in-house include medical review and clinical assessment, GxP-regulated manufacturing operations, direct interactions with regulatory agencies, strategic commercial planning, and any activity requiring access to pre-public clinical data under strict confidentiality protocols.

Companies using virtual assistant services for eligible administrative functions report cost reductions of 55 to 70 percent on those specific roles. For a pharma company spending $2 million annually on administrative support staff, shifting 40 percent of those functions to a VA model could save $440,000 to $560,000 per year without affecting regulated operations.

---

10. Total staffing cost: a worked example for a mid-size pharma company

Below is the annualized staffing cost for a pharmaceutical company with about 500 employees spread across R&D, regulatory, commercial, manufacturing, and admin.

At $82 million in annual staffing costs for a 500-person company generating $400 to $600 million in revenue, labor accounts for 14 to 21 percent of revenue before adding CRO, CMO, and other outsourced labor spend. When those vendor costs are included, total workforce-related spend typically reaches 30 to 40 percent of revenue for a mid-size pharma company.

If the G&A and portions of the commercial support functions shifted to outsourced virtual support at $14,000 to $22,000 per role, the company could save $1.5 to $2.5 million per year on those specific functions while keeping regulated and strategic roles fully staffed internally.

---

11. Key statistics summary

---

Controlling pharmaceutical staffing costs in 2026

The pharma labor market in 2026 comes down to one uncomfortable fact: companies need expensive specialized talent to fill their pipelines, but the revenue base paying for that talent is shrinking as blockbuster patents expire. The patent cliff runs through 2030. The IRA's pricing provisions add a second headwind on the revenue side. This is not going away soon.

More than 22,000 jobs cut by large pharma in a single year. Novo Nordisk, Merck, Bayer, Takeda, CSL, all restructuring at the same time. But layoffs alone do not fix the cost structure. They reduce headcount now while often increasing per-employee costs later, because the people who remain take on bigger workloads and burn out faster, which drives more voluntary turnover.

And that turnover is where the real money goes. At a 15.9 percent voluntary rate and replacement costs that can hit $500,000 for clinical and regulatory specialists, a 5,000-person company spends north of $100 million a year just replacing people who left. Retention spending of $5,000 to $10,000 per employee per year on career development and competitive base adjustments typically returns two to four times the investment.

CROs are now the default for clinical development staffing. The $60.7 billion global market is not a trend, it is the new normal. Most companies that still run large internal clinical operations teams are the exception. Outsourced clinical monitoring, data management, and regulatory writing cost 40 to 60 percent less than equivalent internal capacity once you account for bench time and overhead.

On the admin side, the picture looks a lot like what we found in healthcare industry staffing costs 2026. Regulatory document management, sample tracking, CRM maintenance, medical information triage, vendor coordination: none of these require on-site specialized staff. A $65,000 fully loaded regulatory document specialist versus a $16,000 to $22,000 outsourced virtual assistant doing the same formatting and tracking work. Across 15 to 20 admin roles, the annual savings reach $700,000 to $1 million.

The pharma companies that are managing this well have a few things in common. They use CROs for variable clinical and commercial workloads instead of staffing to peak capacity. They put real money into retaining regulatory affairs and pharmacovigilance specialists instead of assuming they can always hire replacements. And they have sorted out which admin functions can run at lower cost without touching regulated workflows.

That is not a radical operating model change. It is just being honest about which roles justify in-house overhead and which do not, and then acting on it.

---

Sources

1. Bureau of Labor Statistics (BLS) - Occupational Employment and Wage Statistics (OEWS), May 2025
2. Bureau of Labor Statistics (BLS) - Occupational Employment and Wage Statistics, Pharmaceutical Manufacturing NAICS 325400, May 2024
3. PharmaDiversity Job Board - 2025 Pharma Salary Guide
4. Pharmaceutical Technology - State of the Bio/Pharma Workforce: A Comparative Analysis of Employment Trends and Industry Sentiment, 2025
5. Fierce Pharma - Large Pharma Companies Reduced Headcounts by More Than 22K in 2025, 2026
6. Fierce Biotech - Layoff Tracker 2026
7. BioSpace - Biospace Layoff Tracker, 2025
8. Panda International - R&D and Regulatory Affairs Salaries in Biotech and Pharma, 2025
9. ZipRecruiter - Pharmaceutical Regulatory Affairs Salary Data, 2025
10. Glassdoor - Pharmaceutical Sales Representative Average Salary, 2026
11. Salary.com - Sales Representative (Pharmaceuticals) Salary Benchmark, 2026
12. Coherent Market Insights - Contract Research Organization Market Forecast, 2025
13. Retensa - Biotech and Pharma Employee Retention Strategies, 2025
14. Mercer - 2025 US Turnover Surveys and Total Remuneration Survey
15. Hardman & Co - 2024 Pharma Statistics Report, 2025